Abstract
Prostate cancer is one of the diseases worldwide that causes cancer-related deaths in men. Metformin is an antidiabetic drug that has been in use for over two decades for the treatment of Type II Diabetes mellitus (DM2). The purpose of this study was to evaluate the anti-proliferative property of metformin hydrochloride on androgen-sensitive, LNCAP and androgen-insensitive, PC-3 human prostate cancer cell lines at different concentrations (μM and mM) using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Metformin hydrochloride displayed a stronger cytotoxicity on the androgen-insensitive PC-3 than on the androgen-sensitive human prostate cancer cell lines. For both cell lines, the antiproliferative activity of metformin hydrochloride was best displayed at 0.1 mM concentration with average cell death percentage of 60% after 120-hour exposure.
Highlights
Prostate cancer is one of the foremost diseases worldwide that causes cancer-related deaths in men
We describe findings supporting the antiproliferative property of metformin hydrochloride on human prostate cancer cell lines, LNCaP and PC-3
The results indicated that the activity of metformin hydrochloride uses both dose-and time-dependents cytotoxicity (Figure 1)
Summary
Prostate cancer is one of the foremost diseases worldwide that causes cancer-related deaths in men. It is the second most common noncutaneous cancer that affects thousands of men each year in the United States and occurs in older men above the age of 65 years. It was estimated that 26,120 (4.4%) with prostate cancer will die in 2016 out of 180,890 new cases diagnosed [1]. The drug suppresses the hepatic glucose production through a mild and transient inhibition of the mitochondrial respiratory chain complex I [4]. This leads to the activation of AMPK (AMP-activated protein kinase). We describe findings supporting the antiproliferative property of metformin hydrochloride on human prostate cancer cell lines, LNCaP and PC-3
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
